Efficacy of rifampicin in experimental Bacteroides fragilis and Pseudomonas aeruginosa mixed infections. 1985

K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka

Experimental intraabdominal abscesses were produced in mice by intraperitoneal injection of Bacteroides fragilis and Pseudomonas aeruginosa. The therapeutic efficacy of rifampicin and cefsulodin alone, and in combination was investigated in this in-vivo experimental mixed intraabdominal abscess model. Treatment with rifampicin at 10, and 25 mg/kg or cefsulodin at 50, and 100 mg/kg singly or in combinations prevented mortality as compared to 68% mortality rate occurring in the untreated mice. Rifampicin, at 25 mg/kg dose, was very effective in preventing abscess formation and produced bacterial eradication. It prevented abscess formation in 80% of the mice and eradicated both Bacteroides and Pseudomonas in 100% and 75% of the abscesses of the mice. Cefsulodin failed to reduce the incidence of abscess formation, and to eradicate Bact. fragilis from the abscesses, although it significantly decreased Ps. aeruginosa in the abscesses. The combination of rifampicin at 10 mg/kg and cefsulodin at 100 mg/kg was more effective than either of the antibiotics alone and was as effective as rifampicin alone at 25 mg/kg levels. This combination was bactericidal against both organisms in the infected mice.

UI MeSH Term Description Entries
D010532 Peritoneal Diseases Pathological processes involving the PERITONEUM. Peritoneal Disease
D011550 Pseudomonas aeruginosa A species of gram-negative, aerobic, rod-shaped bacteria commonly isolated from clinical specimens (wound, burn, and urinary tract infections). It is also found widely distributed in soil and water. P. aeruginosa is a major agent of nosocomial infection. Bacillus aeruginosus,Bacillus pyocyaneus,Bacterium aeruginosum,Bacterium pyocyaneum,Micrococcus pyocyaneus,Pseudomonas polycolor,Pseudomonas pyocyanea
D011552 Pseudomonas Infections Infections with bacteria of the genus PSEUDOMONAS. Infections, Pseudomonas,Pseudomonas aeruginosa Infection,Infection, Pseudomonas,Pseudomonas Infection,Pseudomonas aeruginosa Infections
D002441 Cefsulodin A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients. Abbott 46811,CGP-7174-E,Cefsulodin Monosodium Salt,Cefsulodin Sodium,Monaspor,Pyocefal,SCE-129,CGP 7174 E,CGP7174E,Monosodium Salt, Cefsulodin,SCE 129,SCE129,Sodium, Cefsulodin
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D000038 Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection. Abscesses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001441 Bacteroides fragilis Gram-negative bacteria occurring in the lower intestinal tracts of man and other animals. It is the most common species of anaerobic bacteria isolated from human soft tissue infections.

Related Publications

K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
April 1988, The Journal of antimicrobial chemotherapy,
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
November 1979, Oral surgery, oral medicine, and oral pathology,
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
April 1984, Infection and immunity,
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
April 1982, The Journal of infectious diseases,
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
January 1993, Chemotherapy,
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
February 1983, Archives of surgery (Chicago, Ill. : 1960),
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
January 1985, Acta oto-laryngologica,
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
December 1987, Surgery, gynecology & obstetrics,
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
July 1981, The Journal of antimicrobial chemotherapy,
K P Fu, and E R Lasinski, and H C Zoganas, and E F Kimble, and E A Konopka
December 2003, Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia,
Copied contents to your clipboard!